RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer: major trial tests promising drug combo
Disease control Recruiting nowThis large, late-stage study is testing whether new drug treatments can better control multiple myeloma that has come back or stopped responding to prior therapies. It will compare two approaches using an investigational drug called linvoseltamab—given alone or combined with carf…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Scientists target genetic flaw in relapsed blood cancer with new pill combo
Disease control Recruiting nowThis study is testing a new combination of two oral drugs, mirdametinib and sirolimus, for adults with advanced multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find a safe dose and see if the drugs can help control the cancer in pat…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
Could a new scan spot returning cancer sooner?
Diagnosis Recruiting nowThis study is testing if a new type of imaging scan can better detect multiple myeloma, a blood cancer, compared to the scan currently used. Researchers want to see if this new scan can find returning disease earlier, which could help doctors start treatment sooner. About 60 adul…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Mar 27, 2026 12:40 UTC